Figure 3.
![aGVHD II-IV. (A) We observed a tendency towards less aGVHD in patients having MSD (P = .071). (B) Patients receiving allo-HSCT during infancy (<13 months) suffered significanlty less aGVHD than older patients (P = .008). (C) A matched CMV serostatus correlated to less aGVHD (P = .018). (D) Predicted OS in patients according to patients’ aGVHD at day 30. The survival probability of OS was significatly reduced in patients developing aGVHD II-IV by day 30 (HR = 3.6 [95% CI 1.43-9.14]; P = .006).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/5/1/10.1182_bloodadvances.2020002185/2/advancesadv2020002185f3.png?Expires=1735842892&Signature=jBQk1lVsNj6b21pj~J~sZ1t7TBt-VBtt5HdyMYtREb0y-RnQ5FNqerPUxPpZL0ImRZOvj99d5329UhkcXVWCGuidYjoLy7KXozMB6AbXt9vMT5r4nNKltPZz7QxJ0i1TMAaTfpF0bjqvlNgI69cj3Qca1dWMeSZXQkKeNZoio~jSI1PYm7NW5N7ypOUBjR~VfFRkYxhPmQJuArtpJNK4xH55grSYjKQMVzlF4pDhc-jvQyoiEgq4ba4FKA4U2OY3bpMp4j7NI8cq3WauUHRRqFWWTcZ3IWdnSJhNeekp~63RMHLeWXUm6QTJS24F6tMYq-MFdEWlfqGBicsT0qNLWA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
aGVHD II-IV. (A) We observed a tendency towards less aGVHD in patients having MSD (P = .071). (B) Patients receiving allo-HSCT during infancy (<13 months) suffered significanlty less aGVHD than older patients (P = .008). (C) A matched CMV serostatus correlated to less aGVHD (P = .018). (D) Predicted OS in patients according to patients’ aGVHD at day 30. The survival probability of OS was significatly reduced in patients developing aGVHD II-IV by day 30 (HR = 3.6 [95% CI 1.43-9.14]; P = .006).